Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial

References

• Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–179. doi:10.1016/j.semcancer.2019.09.015
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874. doi:10.1200/JCO.2010.33.4235
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877–1883. doi:10.1093/annonc/mdv276
   PubMed Web of Science ®Google Scholar
• Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a Phase 3, open-label, randomized study. Ann Oncol. 2017;28(10):2443–2450. doi:10.1093/annonc/mdx359
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. doi:10.1016/S1470-2045(09)70364-X
   PubMed Web of Science ®Google Scholar
• Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128. doi:10.1200/JCO.2011.36.8456
   PubMed Web of Science ®Google Scholar
• Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–59. doi:10.1093/annonc/mds214
   PubMed Web of Science ®Google Scholar
• Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10–i19. doi:10.1093/annonc/mdx703
   PubMed Web of Science ®Google Scholar
• Ralki M, Maes B, Pat K, Wynants J, Cuppens K. Triple trouble: a case of multiple resistance mechanisms after first generation EGFR-TKI in NSCLC. Case Rep Oncol. 2019;12(2):625–630. doi:10.1159/000502214
   PubMed Web of Science ®Google Scholar
• Otsubo K, Sakai K, Takeshita M, et al. Genetic profiling of non-small cell lung cancer at development of resistance to first- or second-generation EGFR-TKIs by CAPP-Seq analysis of circulating tumor DNA. Oncologist. 2019;24(8):1022–1026. doi:10.1634/theoncologist.2019-0101
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Codony-Servat J, Bracht JWP, et al. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. Expert Rev Respir Med. 2019;13(10):1019–1028. doi:10.1080/17476348.2019.1656068
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Katakura S, Kamimaki C, et al. Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients: a meta-analysis. Thorac Cancer. 2021;12(7):1096–1105. doi:10.1111/1759-7714.13878
   PubMed Web of Science ®Google Scholar
• Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 2018;7(11):212. doi:10.3390/cells7110212
   PubMed Web of Science ®Google Scholar
• Del Re M, Crucitta S, Gianfilippo G, et al. Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. Int J Mol Sci. 2019;20(16):3951. doi:10.3390/ijms20163951
   PubMed Web of Science ®Google Scholar
• Gao J, Li HR, Jin C, Jiang JH, Ding JY. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clin Transl Oncol. 2019;21(10):1287–1301. doi:10.1007/s12094-019-02075-1
   PubMed Web of Science ®Google Scholar
• Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1–10. doi:10.1016/j.ctrv.2018.02.006
   PubMed Web of Science ®Google Scholar
• Sugawara S, Oizumi S, Minato K, et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol. 2015;26(5):888–894. doi:10.1093/annonc/mdv063
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al.; North-East Japan Study Group. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J Clin Oncol. 2020;38(2):115–123. doi:10.1200/JCO.19.01488
   PubMed Web of Science ®Google Scholar
• Cheng Y, Murakami H, Yang PC, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266. doi:10.1200/JCO.2016.66.9218
   PubMed Web of Science ®Google Scholar
• Choi HC, Kim JH, Kim HS, et al. Comparison of the RECIST 1.0 and RECIST 1.1 in non-small cell lung cancer treated with cytotoxic chemotherapy. J Cancer. 2015;6(7):652–657. doi:10.7150/jca.11794
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017;35(34):3823–3829. doi:10.1200/JCO.2017.72.5069
   PubMed Web of Science ®Google Scholar
• Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 2001. doi:10.1002/0471142905.hg0908s07
   PubMedGoogle Scholar
• Li C, He Q, Liang H, et al. Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer: a meta-analysis. Front Oncol. 2020;10:290. doi:10.3389/fonc.2020.00290
   PubMed Web of Science ®Google Scholar
• Li YX, Yang JY, Xu YF, et al. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC. Math Biosci Eng. 2019;16(5):5687–5696. doi:10.3934/mbe.2019283
   PubMed Web of Science ®Google Scholar
• Pilotto S, Rossi A, Vavalà T, et al. Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study. Clin Lung Cancer. 2018;19(1):93–104. doi:10.1016/j.cllc.2017.05.016
   PubMed Web of Science ®Google Scholar
• Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open. 2020;5(6):e001011. doi:10.1136/esmoopen-2020-001011
   PubMed Web of Science ®Google Scholar
• Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of non-small cell lung cancer with EGFR-mutations. J UOEH. 2019;41(2):153–163. doi:10.7888/juoeh.41.153
   PubMedGoogle Scholar
• Xu R, Shao H, Zhu J, Ju Q, Shi H. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: pooled analysis and subgroup analysis of efficacy and safety. Medicine. 2019;98(13):e14135. doi:10.1097/MD.0000000000014135
   PubMed Web of Science ®Google Scholar
• Iwama E, Nakanishi Y, Okamoto I. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(3):267–276. doi:10.1080/14737140.2018.1432356
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zeng K, Zhao S, et al. Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Ther Adv Med Oncol. 2019;11:1758835919891652. doi:10.1177/1758835919891652
   Web of Science ®Google Scholar
• Rebuzzi SE, Alfieri R, La Monica S, Minari R, Petronini PG, Tiseo M. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit Rev Oncol Hematol. 2020;146:102820. doi:10.1016/j.critrevonc.2019.102820
   PubMed Web of Science ®Google Scholar
• Wang S, Gao A, Liu J, Sun Y. First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice? Cancer Chemother Pharmacol. 2018;81(3):443–453. doi:10.1007/s00280-017-3516-1
   PubMed Web of Science ®Google Scholar
• Yang JC, Cheng Y, Murakami H, et al. A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival and biomarker analysis. J Thorac Oncol. 2020;15(1):91–100. doi:10.1016/j.jtho.2019.09.008
   PubMed Web of Science ®Google Scholar
• McCoach CE, Blumenthal GM, Zhang L, et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017;28(11):2707–2714. doi:10.1093/annonc/mdx414
   PubMedGoogle Scholar
• da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69. doi:10.1146/annurev-pathol-011110-130206
   PubMed Web of Science ®Google Scholar
• Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):612–623. doi:10.1016/j.jtho.2016.12.014
   PubMed Web of Science ®Google Scholar
• Zhou J, Ben S. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. Thorac Cancer. 2018;9(2):228–233. doi:10.1111/1759-7714.12568
   PubMed Web of Science ®Google Scholar
• Zhuo M, Zheng Q, Zhao J, et al. Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. Chin J Cancer Res. 2017;29(6):553–560. doi:10.21147/j.issn.1000-9604.2017.06.10
   PubMed Web of Science ®Google Scholar
• Deng W, Lei Y, Liu S, et al. Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. Chin J Cancer Res. 2016;28(3):339–347. doi:10.21147/j.issn.1000-9604.2016.03.08
   PubMed Web of Science ®Google Scholar
• Koyama N, Watanabe Y, Iwai Y, et al. Distinct benefit of overall survival between patients with non-small-cell lung cancer harboring EGFR exon 19 deletion and exon 21 L858R substitution. Chemotherapy. 2017;62(3):151–158. doi:10.1159/000454944
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014;9(9):e107161. doi:10.1371/journal.pone.0107161
   PubMed Web of Science ®Google Scholar
• Zhou S, Hu X, Wang Y, et al. Clinicopathologic characteristics and outcome of patients with different EGFR mutations. Asia Pac J Clin Oncol. 2019;15(3):166–171. doi:10.1111/ajco.13072
   PubMed Web of Science ®Google Scholar
• Liu HL, Han G, Peng M, et al. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: a retrospective analysis. J Huazhong Univ Sci Technolog Med Sci. 2017;37(6):864–872. doi:10.1007/s11596-017-1819-4
   PubMedGoogle Scholar
• Wang H, Huang J, Yu X, et al. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. J Cancer Res Clin Oncol. 2014;140(11):1901–1909. doi:10.1007/s00432-014-1709-0
   PubMed Web of Science ®Google Scholar
• Ke EE, Zhou Q, Zhang QY, et al. A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol. 2017;12(9):1368–1375. doi:10.1016/j.jtho.2017.05.018
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59. doi:10.1126/scitranslmed.3002356
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-2246
   PubMed Web of Science ®Google Scholar
• Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11(8):473–481. doi:10.1038/nrclinonc.2014.104
   PubMed Web of Science ®Google Scholar
• Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390–401. doi:10.1016/j.apsb.2015.07.001
   PubMed Web of Science ®Google Scholar
• Lu X, Yu L, Zhang Z, Ren X, Smaill JB, Ding K. Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: current developments in medicinal chemistry. Med Res Rev. 2018;38(5):1550–1581. doi:10.1002/med.21488
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. doi:10.1186/s12943-018-0777-1
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi:10.1126/scitranslmed.3002003
   PubMed Web of Science ®Google Scholar
• Passaro A, Guerini-Rocco E, Pochesci A, et al. Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment. Pharmacol Res. 2017;117:406–415. doi:10.1016/j.phrs.2017.01.003
   PubMed Web of Science ®Google Scholar
• Li H, Wang J, Zhang G, et al. Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world. J Thorac Dis. 2020;12(3):550–557. doi:10.21037/jtd.2019.12.122
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. FLAURA investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Al-Quteimat OM, Amer AM. A review of osimertinib in NSCLC and pharmacist role in NSCLC patient care. J Oncol Pharm Pract. 2020;26(6):1452–1460. doi:10.1177/1078155220930285
   PubMed Web of Science ®Google Scholar
• Malapelle U, Ricciuti B, Baglivo S, et al. Osimertinib. Recent Results Cancer Res. 2018;211:257–276.
   PubMedGoogle Scholar
• Nishikawa S, Kimura H, Koba H, et al. Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance. J Thorac Dis. 2018;10(3):1431–1439. doi:10.21037/jtd.2018.01.144
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhu L, Xia B, et al. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study. Cancer Commun (Lond). 2018;38(1):28.
   PubMedGoogle Scholar
• Chan DLH, Toh GLX, Goh LL. Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients. Exp Mol Pathol. 2020;116:104515. doi:10.1016/j.yexmp.2020.104515
   PubMed Web of Science ®Google Scholar
• Xiong L, Cui S, Ding J, et al. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Oncotarget. 2017;8(38):63846–63856. doi:10.18632/oncotarget.19139
   PubMedGoogle Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Takeda M, Nakagawa K. First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-Naive EGFR mutation-positive non-small cell lung cancer? Int J Mol Sci. 2019;20(1):146. doi:10.3390/ijms20010146
   PubMed Web of Science ®Google Scholar
• Choo JR, Tan CS, Soo RA. Treatment of EGFR T790M-positive non-small cell lung cancer. Target Oncol. 2018;13(2):141–156. doi:10.1007/s11523-018-0554-5
   PubMed Web of Science ®Google Scholar
• Russo A, Franchina T, Ricciardi GRR, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol. 2017;117:38–47. doi:10.1016/j.critrevonc.2017.07.003
   PubMed Web of Science ®Google Scholar
• Joo JW, Hong MH, Shim HS. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Lung Cancer. 2018;121:12–17. doi:10.1016/j.lungcan.2018.04.013
   PubMed Web of Science ®Google Scholar
• Shetty V, Babu S. Management of CNS metastases in patients with EGFR mutation-positive NSCLC. Indian J Cancer. 2019;56(Supplement):S31–S37. doi:10.4103/ijc.IJC_455_19
   PubMedGoogle Scholar
• Ahluwalia MS, Becker K, Levy BP. Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non-small cell Lung cancer. Oncologist. 2018;23(10):1199–1209. doi:10.1634/theoncologist.2017-0572
   PubMed Web of Science ®Google Scholar
• Li MX, He H, Ruan ZH, et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer. 2017;17(1):245. doi:10.1186/s12885-017-3165-0
   PubMedGoogle Scholar
• Zhou Y, Wang B, Qu J, et al. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. Lung Cancer. 2020;150:178–185. doi:10.1016/j.lungcan.2020.10.018
   PubMed Web of Science ®Google Scholar
• He ZY, Li MF, Lin JH, Lin D, Lin RJ. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag Res. 2019;11:2129–2138. doi:10.2147/CMAR.S184922
   PubMed Web of Science ®Google Scholar